Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Updated: 7/18/2017

Hairy Cell Leukemia (HCL)

0%
Topic
Review Topic
0
0
N/A
N/A
Questions
2
0
0
0%
0%
Evidence
3
0
0
Topic
  • Snapshot
    • A 50-year-old man presents to his primary care physician for an annual visit. He has no complaints. His past medical history includes hypertension, hypercholesterolemia, and rheumatoid arthritis. He goes for routine blood tests today, which reveals marked pancytopenia. A peripheral blood smear is done, showing cells with hair-like projections. hairy cells
  • Introduction
    • Indolent leukemia of mature B-cells with infiltration of bone marrow and spleen
    • Epidemiology
      • median onset 50-55 years of age
      • male > female 4.5x
    • Associated conditions
      • autoimmune conditions
    • Characteristics
      • “hairy cells” with filamentous, hair-like projections
      • tartrate-resistant acid phosphatase (TRAP) +
    • Prognosis
      • good prognosis, especially with good response to purine analogs
  • Presentation
    • Symptoms
      • pancytopenia from infiltration of bone marrow
        • fatigue
        • infections
        • bleeding
        • anemia
    • Physical exam
      • splenomegaly from infiltration of spleen
      • no lymphadenopathy
  • Evaluation
    • Peripheral blood smear
      • B-cells with hairy projections
      • + TRAP stain (tartrate-resistant acid phosphatase)
    • Flow cytometry
      • CD11c+ and CD2+
      • CD5- and CD10-
    • Bone marrow aspirate
      • dry tap due to marrow fibrosis
    • CBC
      • anemia
      • thrombocytopenia
      • leukopenia
  • Differential Diagnosis
    • Non-Hodgkin lymphoma
    • Mantle cell lymphoma
  • Treatment
    • Purine analogs
      • first line: cladribine (2-CDA)
      • pentostatin
      • both inhibit adenosine deaminase
      • recall this is the same enzyme deficiency seen in SCID leading to B-cell dysfunction
  • Complications
    • Complications
      • infections
      • increased risk of malignancy
Flashcards (0)
Cards
1 of 0
Questions (2)
Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK

(M1.ON.14.23) A 66-year old man presents to your clinic with a complaint of abdominal fullness and six months of worsening fatigue, weakness, and easy bruising. On physical exam, vital signs are stable, but you note marked splenomegaly and scattered ecchymoses. Labs are noteworthy for a hematocrit of 25%, total white blood cell count of 3000/uL, and platelet count of 35,000/uL. A peripheral blood smear is shown in Figure A; a tartrate-resistant acid phosphatase (TRAP) assay comes back positive. On further diagnostic workup, a bone marrow aspirate does not yield a sample due to extensive fibrosis. Which of the following is the first-line agent for the treatment of this condition?

QID: 104663
FIGURES:

Vincristine

7%

(19/256)

Rituximab

18%

(47/256)

Cyclophosphamide

12%

(30/256)

Cladribine

52%

(132/256)

Methotrexate

9%

(22/256)

M 2 E

Select Answer to see Preferred Response

Evidence (3)
VIDEOS & PODCASTS (1)
EXPERT COMMENTS (12)
Private Note